Cited by 149Treatment of Major DepressionElectroconvulsive Therapy StudiesTranscranial Magnetic Stimulation Studies

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression

George, Duncan, Gálvez, Verònica, Martin, Donel, Kumar, Divya, Leyden, John, Hadzi-Pavlovic, Dusan, Harper, Simon, Brodaty, Henry, Glue, Paul, Taylor, Rohan, Mitchell, Philip B., Loo, Colleen K.·2017·The American Journal of Geriatric Psychiatry

DOI 10.1016/j.jagp.2017.06.007

Open this paper in CoChat — free account

Abstract

Objective To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-resistant depression. Secondary aims were to examine if repeated treatments were safe and more effective in inducing or prolonging remission than a single treatment. Methods In this double-blind, controlled, multiple-crossover study with a 6-month follow-up (randomized controlled trial [RCT] phase), 16 participants (≥60 years) with treatment-resistant depression who relapsed after remission or did not remit in the RCT were administered an open-label phase. Up to five subcutaneous doses of ketamine (0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg) were administered in separate sessions (≥1 week apart), with one active control (midazolam) randomly inserted (RCT phase). Twelve ketamine treatments were given in the open-label phase. Mood, hemodynamic, and psychotomimetic outcomes were assessed by blinded raters. Remitters in each phase were followed for 6 months. Results Seven of 14 RCT-phase completers remitted with ketamine treatment. Five remitted at doses below 0.5 mg/kg. Doses ≥ 0.2 mg/kg were significantly more effective than midazolam. Ketamine was well tolerated. Repeated treatments resulted in higher likelihood of remission or longer time to relapse. Conclusion Results provide preliminary evidence for the efficacy and safety of ketamine in treating elderly depressed. Dose titration is recommended for optimizing antidepressant and safety outcomes on an individual basis. Subcutaneous injection i…

Integrity signals

Registry

Crossref · 10.1016/j.jagp.2017.06.007

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Depression, chronic diseases, and decrements in health: results from the World Health Surveys
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61415-9 · Cited by 4,070
Depression in Older Adults
Fiske, A., Wetherell, J. L., & Gatz, M. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153621 · Cited by 2,353
CUMULATIVE ILLNESS RATING SCALE
Linn, B. S., Linn, M. W., & Gurel, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,332
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression.
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339

Show all 29 references

Sorted by citations

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Novel and emerging treatments for major depression
Marwaha, S., Palmer, E. R., Suppes, T. M., Cons, E., Young, A. H., & Upthegrove, R. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 618
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Self-citation
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Biological factors influencing depression in later life: role of aging processes and treatment implications
Szymkowicz, S. M., Gerlach, A., Homiack, D., & Taylor, W. D. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02464-9 · Cited by 234
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C. A., Vázquez, G. H., & Loo, C. K. A. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102127 · Cited by 191
Self-citation
The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases
Behlke, L. M., Lenze, E. J., & Carney, R. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00763-z · Cited by 125
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur
Swainson, J., McGirr, A., Blier, P., Brietzke, E. M., Richard‐Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 124
Ketamine for depression
Jelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 112
The Neuropsychology of Anxiety
McNaughton, N., & Gray, J. A. (2024) · doi:10.1093/oso/9780198843313.001.0001 · Cited by 99
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
Loo, C. K. A., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P. B., Glue, P., Sarma, S., Gálvez, V., Hadži-Pavlović, D., et al. (2023) · The British Journal of Psychiatry · doi:10.1192/bjp.2023.79 · Cited by 86
Self-citation
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 78
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., Saah, T. C., Dunlop, B. W., & McDonald, W. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.025 · Cited by 70
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review
Vincenzo, J. D. D., Siegel, A. N., Lipsitz, O., Ho, R., Teopiz, K. M., Ng, J., Lui, L. M. W., Lin, K., Cao, B., Rodrigues, N. B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.058 · Cited by 64
Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R )-hydroxynorketamine
Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
Molecular Basis of Late-Life Depression
Kuo, C.-Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147421 · Cited by 62
Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.07.003 · Cited by 48
Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019
Corkery, J., Hung, W.-C., Claridge, H., Goodair, C., Copeland, C. S., & Schifano, F. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211021588 · Cited by 52
Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis
Ren, L., Deng, J. V., Min, S., Peng, L., & Chen, Q. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.003 · Cited by 46
Development of the Ketamine Side Effect Tool (KSET)
Short, B. L., Dong, V., Gálvez, V., Vulovic, V., Martin, D. M., Bayes, A. J., Zarate, C. A., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.120 · Cited by 47
Self-citation
Subcutaneous Ketamine in Depression: A Systematic Review
Cavenaghi, V. B., da Costa, L. P., Lacerda, A. L. T., Hirata, E. S., Miguel, E. C., & Fráguas, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.513068 · Cited by 44
Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial
Lin, C., Wang, S., & Lane, H. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac006 · Cited by 44
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 43
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series
Lipsitz, O., Di Vincenzo, J. D., Rodrigues, N. B., Cha, D. S., Lee, Y., Greenberg, D., Teopiz, K. M., Ho, R. C., Cao, B., Lin, K., et al. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.12.032 · Cited by 40
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
Oughli, H. A., Gebara, M. A., Ciarleglio, A., Lavretsky, H., Brown, P. J., Flint, A. J., Farber, N. B., Karp, J. F., Mulsant, B. H., Reynolds, C. F., et al. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.11.013 · Cited by 40
Personalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 43
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 43
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
Guo, W., Machado‐Vieira, R., Mathew, S. J., Murrough, J. W., Charney, D. S., Grunebaum, M., Oquendo, M. A., Kadriu, B., Akula, N., Henter, I. D., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0311-7 · Cited by 37
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity
Lucchese, A. C., Sarin, L. M., Magalhães, E. T. P., Sant, L. C. D., Puertas, C. B., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R. S., Surjan, J. C., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120978398 · Cited by 36
Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting
Sinyor, M., Williams, M., Belo, S., Orser, B. A., Vincent, M., Mah, L., Zarate, C. A., Castel, S., LEVITT, A. J., & Schaffer, A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.073 · Cited by 39
Ketamine for depression clinical issues
Iqbal, S., & Mathew, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.005 · Cited by 33
Safety of Repeated Administration of Parenteral Ketamine for Depression
Feifel, D., Dadiomov, D., & C. Lee, K. (2020) · Pharmaceuticals · doi:10.3390/ph13070151 · Cited by 31
Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders
Vankawala, J., Naples, G., Avila-Quintero, V. J., Ramírez, K. L., Flores, J. M., Bloch, M. H., & Dwyer, J. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.549080 · Cited by 30
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial
Lijffijt, M., Murphy, N., Iqbal, S., Green, C. E., Iqbal, T., Chang, L. C., Haile, C. N., Hirsch, L. C., Ramakrishnan, N., Fall, D. A., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01242-9 · Cited by 31
Urothelial toxicity of esketamine in the treatment of depression
Findeis, H., Sauer, C., Cleare, A. J., Bauer, M., & Ritter, P. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05611-y · Cited by 29
Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression
Sant, L. C. D., Sarin, L. M., Magalhães, E. T. P., Lucchese, A. C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R. S., Surjan, J. C., Steglich, M. S., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120922955 · Cited by 25
Can we confidently use ketamine as a clinical treatment for depression?
Loo, C. K. A. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30480-7 · Cited by 24
Self-citation
Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants
Derntl, B., Hornung, J., Şen, Z. D., Čolić, L., Li, M., & Walter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00616 · Cited by 23
A systematic review of ketamine for the treatment of depression among older adults
Gupta, A., Dhar, R., Patadia, P., Funaro, M. C., Bhattacharya, G., Farheen, S. A., & Tampi, R. R. (2020) · International Psychogeriatrics · doi:10.1017/s1041610220000903 · Cited by 21
Stress and Ketamine, Bimodal Influence on Cognitive Functions
Trofimiuk, E., Wielgat, P., Braszko, J. J., & Car, H. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.12.030 · Cited by 20
Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression
Zhou, Y., Liu, W.-J., Wang, C., Zheng, W., Lan, X., Weng, S.-Y., & Ning, Y. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936909 · Cited by 19
Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression
Pennybaker, S. J., Roach, B. J., Fryer, S. L., Badathala, A., Wallace, A., Mathalon, D. H., & Marton, T. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05939-z · Cited by 17
Blinding Integrity in Psychedelic Randomized Clinical Trials
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 19
Systematic review of clinical effectiveness of interventions for treatment resistant late-life depression
Moyano, B. P., Bautista, D. G., Ibarra, K. J. P., Mueller, C., von Gunten, A., Vandel, P., Ranjbar, S., Howard, R. J., Young, A. H., Stewart, R. J., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102710 · Cited by 19
Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 16
Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants
Singh, J. B., Fedgchin, M. M., Daly, E., & Drevets, W. C. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.002 · Cited by 18
Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice
Mastrodonato, A., Pavlova, I., Kee, N., Pham, V. A., McGowan, J. C., Mann, J. J., & Denny, C. A. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac020 · Cited by 15
Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study
Palhano-Fontes, F., Cavalcanti-Ribeiro, P., Gonçalves, K. T. D. C., de Almeida, V. R. N., Barbosa, D. C., Ferreira, M. A. D. A., Bolcont, R., Souza, L. C. A. M. D., dos Santos, N. C., Lopes, E. I. T. C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.141 · Cited by 13
Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review
Gómez-Busto, F. J., & Ortiz, M. I. (2020) · PubMed Central · doi:10.36131/cnfioritieditore20200606 · Cited by 12
“The study by George et al. (2017), a double blind, controlled, multiple-crossover study with 6-month follow up, aimed to assess the efficacy and safety of subcutaneous ketamine as a novel therapeutic method for treatment-resistant depression in geriatric patients.”
Background
Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression
Lopes, E. I. T. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Gonçalves, K. T. D. C., Nunes, E. A., Lima, N. B. D. M., dos Santos, N. C., de Brito, A. J. C., de Araújo, D. B., & Coelho, N. L. G. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.020 · Cited by 12
Ketamine treatment for depression: A model of care
Bayes, A. J., Dong, V., Martin, D. M., Alonzo, A., Kabourakis, M., & Loo, C. K. A. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211039166 · Cited by 12
Self-citation
Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability
Sukhdeo, R., Tamura, J. K., Dri, C. E., & McIntyre, R. S. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.08.001 · Cited by 12
A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders
Hovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 13
Efficacy of esketamine nasal spray for treatment-resistant depression: a meta-analysis of randomized controlled studies
Ouyang, Y., & Li, J. (2025) · Medicine · doi:10.1097/md.0000000000041495 · Cited by 10
Treatment-resistant late-life depression prevalence and clinical/sociodemographic correlates: An electronic health records study
Moyano, B. P., Orgeta, V., von Gunten, A., Vandel, P., Ma, R., Stewart, R. J., & Mueller, C. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.169 · Cited by 10
Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice
Hussain, S., Gale, C. K., Sarma, S., Smith, J. P., Bayes, A. J., & Loo, C. K. A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251333577 · Cited by 10
Self-citation
Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression
O’Brien, B., Green, C. E., Jurdi, R. K. A., Chang, L. C., Lijffijt, M., Iqbal, S., Iqbal, T., Swann, A. C., & Mathew, S. J. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100432 · Cited by 10
Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
Sant, L. C. D., Sarin, L. M., Lucchese, A. C., Magalhães, E. T. P., Tuena, M. A., Nakahira, C., Porto, J. A. D., Lacerda, A. L. T., & Mari, J. D. J. (2022) · Pharmaceuticals · doi:10.3390/ph16010031 · Cited by 10
A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression
Zheng, W., Zhou, Y., Wang, C., Lan, X., & Ning, Y. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.120 · Cited by 10
Fast-acting antidepressant-like effects of ketamine in aged male rats
Hernández‐Hernández, E., Ledesma‐Corvi, S., Jornet-Plaza, J., & García-Fuster, M. J. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00636-y · Cited by 7
Single Subcutaneous Ketamine Dose Followed by Oral Ketamine for Depression Symptoms in Hospice Patients: A Case Series
Latuga, N. M., Luczkiewicz, D. L., Grant, P. C., Levy, K., Hansen, E., & Kerr, C. W. (2021) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2021.1883182 · Cited by 9
Acute (R,S)-Ketamine Administration Induces Sex-Specific Behavioral Effects in Adolescent but Not Aged Mice
Mastrodonato, A., Pavlova, I., Kee, N., McGowan, J. C., Mann, J. J., & Denny, C. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.852010 · Cited by 9
Ketamine in depression and electroconvulsive therapy
Rozet, I. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001039 · Cited by 10
Ketamine for Depression in Older Adults
Subramanian, S., & Lenze, E. J. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.01.005 · Cited by 9
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review
Kerr‐Gaffney, J., Tröger, A., Caulfield, A., Ritter, P. S., Rucker, J., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251350267 · Cited by 8
Treatment of Behavior Disturbances with Ketamine in a Patient Diagnosed with Major Neurocognitive Disorder
Steenblock, D. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.02.006 · Cited by 8
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8
Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)—Phase II single-arm open-label feasibility study
Lee, W., Sheehan, C., Chye, R., Chang, S., Bayes, A. J., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290876 · Cited by 9
Self-citation
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program
Veraart, J. K. E., Smith-Apeldoorn, S. Y., van der Meij, A., Spijker, J., Schoevers, R. A., & Kamphuis, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251332831 · Cited by 9
Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R)
Bayes, A. J., Cao, T. V., Barreiros, A. R., Massaneda‐Tuneu, C., Dong, V., Thornton, N. L. R., Glozier, N., Beesley, L., Moreno, D., Gálvez, V., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116334 · Cited by 7
Self-citation
Keynote Lecture
Reniers, P., Leontjevas, R., Slavi Stoyanov, A., Knippenberg, I. A. H., van Lankveld, J. J. D. M., & Gerritsen, D. L. (2019) · International Psychogeriatrics · doi:10.1017/s1041610219001339 · Cited by 6
Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study)
Lee, W., Sheehan, C., Chye, R., Chang, S., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052312 · Cited by 7
Self-citation
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 7
A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression
Can, A., Hermens, D. F., & Lagopoulos, J. (2022) · Clinical Case Reports · doi:10.1002/ccr3.6675 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study
Anzolin, A. P., Baldez, D. P., Montezano, B. B., Kapczinski, F. P., Belmonte-de-Abreu, P. S., & Kauer‐Sant’Anna, M. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115915 · Cited by 5
Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein
Cavalcanti-Ribeiro, P., Souza, L. C. A. M. D., Tavares, V. D. D. O., de Almeida, R. N., Lima, N. B. D. M., Gonçalves, K. T. D. C., Lopes, E. I. T. C., Bolcont, R., de Brito, A. J. C., Falchi-Carvalho, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120877 · Cited by 4
Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence
Mario, A., Leccisotti, I., Claudia, M. M., Bellomo, A., Panza, F., Tommaso, C., & Madia, L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118199 · Cited by 6
Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities
Rocha, F. L., Cunha, U. G. D. V., Duarte, D. B., & Hara, C. (2022) · CNS Spectrums · doi:10.1017/s1092852922000773 · Cited by 5
A New Solution to an Age-old Problem: A Review of Ketamine and Esketamine for Treatment-resistant Depression in Late Life
Balaram, K., van Dyck, L. I., Wilkins, K. M., & Maruca-Sullivan, P. E. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00389-1 · Cited by 5
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult
Blaszczyk, A. T., Mathys, M. L., & Le, J. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01051-3 · Cited by 9
Depression, Anxiety, and Other Mood Disorders
Jalil, J., Volle, D. C., Zhu, T., & Sassounian, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_88 · Cited by 7
Ketamine for resistant depression: a scoping review.
Eduardo, T.-Q., Acero-González, D. Á., Mateo, L., Melanie, L.-Z., Valentina, P.-F., David, C., Collazos, E., Natalia, R.-S., Andrés, V.-C., Angel, R.-O., et al. (2022) · PubMed Central · Cited by 5
Clinical use of ketamine in psychiatric disorders
Dehestani, S., Mohammadpour, A. H., Sadjadi, S. A., Sathyapalan, T., & Sahebkar, A. (2022) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2022.05.008 · Cited by 6
Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement
Lowe, D. J. E., Müller, D. J., & George, T. P. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200423094423 · Cited by 5
What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?
Zarate, C. A. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.08.009 · Cited by 6
Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation
Anzolin, A. P., Goularte, J., Pinto, J. V., Belmonte-de-Abreu, P., Cruz, L., Cordova, V., Magalhaes, L. S., Rosa, A., Ceresér, K., & Kauer-Sant'Anna, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1147298 · Cited by 3
The evidence for ketamine treatment in older adults with psychiatric illness: a scoping review
Murphy, K. S., Golden, J. C., Schuster, H., & Tampi, R. R. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223251384803 · Cited by 3
The spectrum of bipolar disorder in older adults
Eyler, L. T., Klaus, F., Dyne, A. V., Ng, H. X., Dols, A., & Sajatovic, M. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02330-4 · Cited by 5
Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Kamphuis, J., Touw, D. J., & Schoevers, R. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177470 · Cited by 4
Recent developments in geriatric psychopharmacology
Aftab, A., Lam, J. A., Liu, F., Ghosh, A., & Sajatovic, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1882848 · Cited by 3
Suizidpräventive Effekte von Ketamin und Esketamin
Plöderl, M., Hengartner, M. P., & Volkmann, C. (2022) · Nervenheilkunde · doi:10.1055/a-1761-3192 · Cited by 2
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians
Elliott, S. I., Katz, R. B., Ostroff, R. B., Ansari, M., Holmes, S. E., & Sanacora, G. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240040 · Cited by 2
Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight
Kutz, C. J., Mistry, A. M., & Dukes, C. H. (2025) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.6619.2025 · Cited by 2
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?
Shadli, S. M., Donegan, C. J., Fahmi, M. S. B. M., Russell, B. R., Glue, P., & McNaughton, N. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241275627 · Cited by 2
Self-citation
Ketamine treatment for depression in elderly inpatients: an observational case series
Römer, B., Maroni, S. S., Fevang, E., Helle, H. B., Stewart, L. H., Aarsland, D., & Vik‐Mo, A. O. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100904 · Cited by 2
Anxiety and personality
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0012 · Cited by 2

Authors: George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., Harper, S., Brodaty, H., Glue, P., Taylor, R., Mitchell, P. B., & Loo, C. K.
Affiliations: Black Dog Institute (AU)
UNSW Sydney (AU)
Royal North Shore Hospital (AU)
Wesley Hospital (AU)
University of Otago (NZ)
Corresponding author: Loo, Colleen K.
ORCID: George, Duncan
Gálvez, Verònica
Martin, Donel
Leyden, John
Brodaty, Henry
Glue, Paul
Mitchell, Philip B.
Loo, Colleen K.
Venue: The American Journal of Geriatric Psychiatry
Publisher: Elsevier BV
Published: 2017-11
Volume: 25
Issue: 11
Pages: 1199-1209
ISSN: 1064-7481 (ISSN-L)
DOI: 10.1016/j.jagp.2017.06.007
OpenAlex: W2625860417
Cited by: 149
References: 29
Citations by year: 2026: 10 · 2025: 17 · 2024: 37 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 16 · 2019: 4 · 2018: 10 · 2017: 4
FWCI: 6.51
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: American Journal of Geriatric Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: NSW Institute of Psychiatry
University of Barcelona
NARSAD
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords: subcutaneous ketamine, treatment-resistant depression, geriatric depression, older adults, dose titration, remission, relapse, psychotomimetic effects, antidepressant efficacy, drug safety
MeSH terms: Aged, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypnotics and Sedatives, Injections, Subcutaneous, Ketamine, Male, Midazolam, Middle Aged, Pilot Projects, Remission Induction, Outcome Assessment, Health Care, Cross-Over Studies, Excitatory Amino Acid Antagonists, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks